Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
McKinsey
Express Scripts

Last Updated: May 30, 2023

SINUVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Sinuva patents expire, and what generic alternatives are available?

Sinuva is a drug marketed by Intersect Ent Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has forty-seven patent family members in twelve countries.

The generic ingredient in SINUVA is mometasone furoate. There are thirty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sinuva

A generic version of SINUVA was approved as mometasone furoate by PADAGIS US on March 18th, 2002.

  Try a Trial

US Patents and Regulatory Information for SINUVA

SINUVA is protected by thirteen US patents.

Patents protecting SINUVA

Systems, devices, and method for treating a sinus condition
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Expandable devices and methods for treating a nasal or sinus condition
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Systems, devices, and method for treating a sinus condition
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Device and methods for treating paranasal sinus conditions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Sinus delivery of sustained release therapeutics
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Methods and devices for crimping self-expanding devices
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Device and methods for treating paranasal sinus conditions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SINUVA

See the table below for patents covering SINUVA around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2014151963 ⤷  Try a Trial
European Patent Office 1605863 ADMINISTRATION DANS UN SINUS D'AGENTS THERAPEUTIQUES A LIBERATION PROLONGEE (SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS) ⤷  Try a Trial
Japan 2018114313 副鼻腔状態を処置するためのシステム、デバイスおよび方法 (SYSTEMS, DEVICES AND METHODS FOR TREATING SINUS CONDITION) ⤷  Try a Trial
China 105188831 Systems, devices, and methods for treating a sinus condition ⤷  Try a Trial
European Patent Office 2298318 Dispositifs et procédés de traitement des affections sinus paranasaux (Device and methods for treating paranasal sinus conditions) ⤷  Try a Trial
Australia 2006231506 Device and methods for treating paranasal sinus conditions ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SINUVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 2022C/520 Belgium ⤷  Try a Trial PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
0112669 96C0002 Belgium ⤷  Try a Trial PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
3043773 132021000000191 Italy ⤷  Try a Trial PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
0548114 SPC/GB97/064 United Kingdom ⤷  Try a Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Boehringer Ingelheim
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.